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Abstract
Background: Primary Sjögren’s syndrome (pSS) is a systemic rheumatic disease in which gastrointestinal (GI) symptoms
are common. Faecal calprotectin (FC) is a non-invasive biomarker that has been suggested to discriminate organic
intestinal disease from functional disorders. The purpose of this study was to explore the usefulness of FC testing in
patients with pSS.
Methods: In total, 56 consecutive patients with pSS and 29 healthy control subjects were included in this cross-sectional
study. FC was measured with a commercially available enzyme-linked immunosorbent assay kit. GI symptoms were
evaluated with the Rome III questionnaire and the Visual Analogue Scale for Irritable Bowel Syndrome. In patients with
pSS, disease activity was estimated using the European League Against Rheumatism (EULAR) Sjögren’s Syndrome Disease
Activity Index (ESSDAI), and patient-reported outcomes were evaluated with the EULAR Sjögren’s Syndrome Patient-
Reported Index.
Results: Patients with pSS had higher levels of FC than healthy control subjects (median 54 μg/g, interquartile range [IQR
20–128]; vs. 20 μg/g [20–43]; p= 0.002). Concomitant organic GI disease was found in 14 patients with pSS and included
inflammatory bowel disease (n = 3), colonic adenoma (n= 2) and GI lymphoma (n = 1). Patients with organic GI disease
had higher FC levels than the other patients with pSS (median 274 μg/g [IQR 61–363] vs. median 34 μg/g [IQR 20–76];
p < 0.001). Although patients with pSS reported abdominal discomfort more frequently than healthy control subjects did,
such symptoms were not associated with organic GI disease or elevated FC levels. FC correlated moderately with ESSDAI.
Excluding patients with organic GI disease, we did not identify any significant association between ESSDAI and FC levels.
Conclusions: GI symptoms are frequent in pSS. Contrary to patient-reported outcomes, elevated FC levels in pSS indicate
possible organic GI disease that warrants further investigation.
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Background
Primary Sjögren’s syndrome (pSS) is a systemic auto-
immune disease characterized by xerostomia and kerato-
conjunctivitis sicca with lymphocytic infiltration of the
exocrine glands. Typically, the disease affects ocular and
oral glands, which is reflected in the current criteria for
this disease [1], but pSS can affect several other organs,
including the lungs, joints and nervous system, as evalu-
ated using the European League Against Rheumatism
(EULAR) Sjögren’s Syndrome Disease Activity Index (ESS-
DAI) [2]. Gastrointestinal (GI) symptoms have been re-
ported to affect a majority of patients with pSS and are
frequently debilitating [3, 4]. Of note, the associations be-
tween patient-reported GI symptoms and objective
markers of GI dysfunction have been weak [5, 6]. Thus,
the majority of patients with pSS have been suggested to
have functional GI disorders such as irritable bowel syn-
drome (IBS) [7–9]. pSS has also been associated with a
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broad spectrum of organic GI diseases, including reflux
esophagitis, chronic atrophic gastritis and coeliac disease,
while an association with inflammatory bowel disease
(IBD) has been debated [10–13]. Furthermore, patients
with pSS are at an overall increased risk of malignancy
[14]. Consequently, GI assessment in pSS is challenging.
Not least is that it is hard to decide which patients to refer
for endoscopy and when.
In primary health care, measurement of faecal calprotec-
tin (FC) has emerged as an objective, easy-to-use biomarker
of GI inflammation. Calprotectin is an inflammatory pro-
tein also known as S100A8/A9 that is surprisingly inert to
degradation and can be readily measured in faeces, even
after storage at room temperature for several days [15]. Fae-
cal levels of calprotectin correlate with intestinal migration
of neutrophils into the intestinal lumen [16]. Increased
levels are seen in GI diseases with an inflammatory compo-
nent, such as IBD, intestinal malignant and pre-malignant
states, and diverticulitis, as well as in upper GI dis-
ease [17, 18]. FC is not elevated in patients with functional
disorders [17]. FC testing has been validated as a sensitive
biomarker for predicting pathological endoscopy in both
the upper and lower GI tracts [18, 19]. In a primary health
care setting, normal FC testing is increasingly being used
to rule out IBD [17, 20]. However, the possible role of FC
as a biomarker in patients with pSS is yet to be explored.
The objective of this study was to investigate the




This cross-sectional study was conducted at the Rheuma-
tology Clinic, Skåne University Hospital, Sweden. Conse-
cutive patients with pSS diagnosed according to the
American-European Consensus Group criteria for Sjögren’s
syndrome were asked to participate [1]. All patients except
one agreed to participate in this study and to deliver a stool
sample. A control group consisting of hospital workers
without any rheumatological or inflammatory GI disease
was also included. Characteristics of the 56 patients and 29
control subjects are described in Table 1.
Clinical assessments
The following data were recorded for all subjects: sex
and age at the time of stool delivery. For all patients with
pSS, the following data were also retrieved: disease activ-
ity according to the ESSDAI [2]; smoking habits; and
current medications, including non-steroidal anti-
inflammatory drugs (NSAIDs) and proton pump inhibi-
tors (PPIs). Furthermore, the patients’ medical records
were scrutinized for concomitant diseases, and any ob-
jectively verified chronic organic GI disease or organic
GI diagnosis based on endoscopic or radiological
examination within 1 year of the time of stool delivery
was noted. Serological testing for coeliac disease during
the previous 8 years was noted.
Laboratory analyses
FC was measured in stool samples with a commercially
available enzyme-linked immunosorbent assay (ELISA)
using a monoclonal antibody (Bühlmann Laboratories,
Schönenbuch, Switzerland) [21]. The lower detection
limit was 30 μg/g. Analyses were done at the Department
of Immunology, Skåne University Hospital, Lund, Sweden.
According to the manufacturer of the ELISA and current
clinical recommendations, a cut-off value of 50 μg/g was
used to discern normal from pathological FC levels. A sec-
ond cut-off value of 150 μg/g was used to indicate sub-
stantial FC elevation in accordance with the latest
recommendations [17]. All patients with pSS were further
analysed regarding C-reactive protein (CRP), erythrocyte
sedimentation rate (ESR), leukocyte count, antibody status
and the required assessments for ESSDAI. All laboratory
assessments were done blinded to the patients’ medical
history.
Questionnaires
All subjects were asked to fill in the Rome III questionnaire,
which is a validated method of identifying functional GI
Table 1 Patient characteristics
Patients (N= 56) Control subjects (N = 29)
Age, yr 62 (53–68) 56 (49–58)
Males/females 2/54 3/26
Disease duration, yr 5 (7–24)
Current/prior/never smokers 7/21/28 2/27





Lip biopsy focus score ≥1 89 %
ESSDAI 7 (2–7)
ESSPRI 6 (5–8)
ESR, mm/h (n = 53) 17 (11–28)
IgG, g/L 13 (10–16)
C3, g/L 1.0 (0.9–1.2)
C4, g/L 0.18 (0.13–0.21)
AECG American-European Consensus Group, ANA anti-nuclear antibodies, anti-SS-A
anti-Sjögren’s syndrome–related antigen A, anti-SS-B anti-Sjögren’s syndrome–
related antigen B; C3 complement component 3, C4 complement component 4,
ESR erythrocyte sedimentation rate, ESSDAI European League Against Rheumatism
Sjögren’s Syndrome Disease Activity Index, ESSPRI European League Against
Rheumatism Sjögren’s Syndrome Patient-Reported Index, IgG immunoglobulin G,
pSS primary Sjögren’s syndrome, RF rheumatoid factor
Values are given as median (interquartile range), number or percentage
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symptoms indicative of IBS [22]. IBS symptom severity was
also assessed using the Visual Analogue Scale for Irritable
Bowel Syndrome (VAS-IBS). The VAS-IBS reflects abdom-
inal pain, diarrhoea, constipation, bloating and flatulence,
vomiting and nausea, psychological well-being and the in-
testinal symptoms’ influence on daily life as evaluated using
seven different VASs, labelled 0–100 mm, where 100 repre-
sents absence of symptoms [23]. Finally, sicca, fatigue and
pain in patients with pSS were evaluated using the EULAR
Sjögren’s Syndrome Patient-Reported Index (ESSPRI) [24].
Statistics
Median and interquartile range (IQR) were used for de-
scriptive data. For comparison of FC levels between
groups, the Mann–Whitney U test was used. Fisher’s exact
test was used for contingency tables. Spearman’s correl-
ation coefficient was used for correlation analyses. FC
values <30 μg/g were approximated to 20 μg/g in all ana-
lyses. Because of the interdependence between different
questionnaire-based variables analysed in this study, we
chose not to use the Bonferroni correction. A two-
sided p value of 0.05 was considered significant. All ana-
lyses were carried out using IBM SPSS Statistics version
20 software (IBM, Armonk, NY, USA).
Ethical approval
This study was approved by the Regional Ethics Com-
mittee, Lund, Sweden (reference number 2011/596). All
subjects gave written informed consent according to the
Declaration of Helsinki.
Results
Increased frequency of pathological FC testing in pSS
Patients with pSS had significantly higher levels of FC than
healthy control subjects (median 54 μg/g [IQR 20–128] vs.
20 μg/g [20–43], p = 0.002) (Fig. 1). Among the patients
with pSS, 52 % (29 of 56) had pathological FC levels
(>50 μg/g) and 21 % (12 of 56) had substantial FC elevation
(>150 μg/g). Corresponding numbers among healthy con-
trol subjects were 20 % and 0 %, respectively.
Organic gastrointestinal disease is common in patients
with pSS and pathological FC levels
Of the 56 patients with pSS, 14 had a concomitant or-
ganic GI disease, including 1 patient with extensive
lymphoma affecting the GI tract (Table 2). Patients with
organic GI disease had significantly higher FC levels
than the other patients (274 μg/g [61–363] vs. 34 μg/g
[20–76], p < 0.001), and 75 % of patients (9 of 12) with
FC >150 μg/g had organic GI disease. The correspond-
ing percentage for patients with FC levels between 50
and 150 μg/g was 18 % (3 of 17), and for patients with
FC within normal range it was 7 % (2 of 27) (Fig. 1). Ex-
cluding patients with organic GI disease, patients with
pSS still had slightly higher levels of FC than healthy
control subjects (34 μg/g [20–76] vs. 20 μg/g [20–43],
p = 0.036). Of note, one patient not categorized as
having organic GI disease but with elevated FC (120 μg/g)
was diagnosed with mucosa-associated lymphoid tissue
lymphoma in the ventricle 18 months after FC testing.
Fig. 1 Elevated levels of faecal calprotectin in primary Sjögren’s
syndrome. Faecal calprotectin levels were higher in patients with
primary Sjögren’s syndrome (n = 56) than in healthy control subjects
(n = 29) (p = 0.002 by Mann–Whitney U test). Subjects with a
concomitant organic gastrointestinal (GI) disease are indicated by
closed triangles; other subjects are represented by open circles
Table 2 Concomitant organic GI diseases in patients with pSS
Diagnosis Number of affected patients
Inflammatory bowel disease, of which 3
Ulcerative colitis 1
Microscopic colitis 1
Unspecified rectal inflammation 1





Gastric antral vascular ectasia 1
Diverticulitis 1a
Gastric binding with surgical complication 1
Total 14
aOne patient had both coeliac disease and diverticulitis
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FC and other clinical markers of disease
Patients with organic GI disease had higher ESSDAI
scores than other patients (10 [4–12] vs. 6 [1–9], p =
0.121). In the whole group, FC correlated with ESSDAI
(rs = 0.32, p = 0.015). When patients with organic GI dis-
ease were excluded, the correlation between FC and
ESSDAI became non-significant (rs = 0.28, p = 0.074).
Further analyses failed to show any difference in FC levels
between users and non-users of NSAIDs (38 vs. 62 μg/g,
p = 0.168) and PPIs (63 vs. 34 μg/g, p = 0.135). In contrast,
FC correlated with biochemical markers of systemic disease,
such as CRP (rs = 0.37, p = 0.006) and ESR (rs = 0.34, p =
0.012), but not with immunoglobulin G or complement
components 3 and 4 (rs = −0.12, p = 0.363; rs = 0.24, p
= 0.070; and rs = −0.07, p = 0.606, respectively).
FC elevation is independent of patient-reported bowel
discomfort in pSS
GI symptoms were evaluated with the VAS-IBS and the
Rome III questionnaire, and questionnaire data were avail-
able for 21 control subjects and 53 patients with pSS.
Bowel discomfort of all kinds was common in pSS
(Tables 3 and 4). Of note, 37 of 51 patients without IBD
had a symptomatology indicative of a functional GI dis-
order. Results from both questionnaires indicated a sub-
stantial heterogeneity encompassing a plethora of GI
symptoms in the pSS group. We did not see any relation-
ship between FC levels and patient-reported GI symptoms
(Tables 3 and 4). Furthermore, we were unable to identify
any association between questionnaire data and organic
GI disease (see Additional file 1). In contrast, average re-
sults from the VAS-IBS correlated with ESSPRI (rs = −0.56,
p < 0.001). Patients with IBS had more pain, as evaluated by
the ESSPRI-Pain sub-scale score, than patients with pSS
without IBS (8 vs. 5, p = 0.013). Four patients in the study
had a clinical diagnosis of fibromyalgia. All of these patients
had a concomitant functional GI disorder.
Discussion
GI symptoms are common in pSS but not always associ-
ated with organic GI disease [3, 6]. In this study, we
found higher levels of FC in patients with pSS than in
healthy control subjects, especially among patients with
organic GI co-morbidities such as IBD, colonic aden-
omas and malignancies. To our knowledge, this is the
first extended report on FC in patients with pSS [25].
FC is a validated biomarker of inflammation. In the field
of gastroenterology, FC is now a routine analysis in the
management of IBD in Europe. An ELISA-based method
for FC analysis has recently received U.S. Food and Drug
Administration approval, and FC is now readily available
in the clinic also in North America [17, 20]. FC is a feas-
ible biomarker, which might explain the high participation
rate in this study of consecutive patients [17].
Today, FC is also frequently used in primary health care,
especially in relation to patients being referred for endos-
copy [19]. Elevated levels of FC are associated not only
with IBD but also with malignant and pre-malignant GI
diseases as well as upper GI pathologies such as reflux
oesophagitis and ulcers and/or erosions. Of note, all con-
ditions in Table 2 have previously been reported to be as-
sociated with pathological FC testing [17, 19, 26, 27].
The origin of FC in pSS is unclear. In this study, we
found elevated FC levels in patients with pSS both with
and without additional organic GI disease compared
with levels in healthy control subjects. We suggest that
FC levels >150 μg/g cannot routinely be explained by
pSS alone, as 9 of 12 patients with FC >150 μg/g had a
concomitant organic GI disease. The situation may be
different for FC levels between 50 and 150 μg/g, for
which organic GI pathology was identified in only 3 of
Table 3 Gastrointestinal discomfort is common in primary Sjögren’s syndrome, based on Visual Analogue Scale for Irritable Bowel
Syndrome results
Domain Control subjects (N = 21) pSS with FC <50 μg/g (N = 25) pSS with FC >50 μg/g (N = 25)
Abdominal pain 97 87a 88b
Diarrhoea 100 94b 91b
Constipation 96 78a 80a
Bloating and flatulence 90 77a 61b
Vomiting and nausea 100 97b 97b
Psychological well-being 93 72b 89
Influence on daily life 99 94a 68b
Average 93 82a 78b
FC faecal calprotectin, pSS primary Sjögren’s syndrome
Values are given as medians in millimetres, and higher values indicate less symptoms. Mann–Whitney U test was used to compare groups. Significant differences
were identified between control subjects in comparison with both pSS groups. No significant differences were identified between patients with pSS with and
without pathological FC testing
ap < 0.05 compared with control subjects
bp < 0.01 compared with control subjects
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17 patients. We can only speculate as to what degree GI
involvement of pSS contributes to the increased FC
levels reported in patients without known organic dis-
ease. Use of both PPIs and NSAIDs has been suggested
to cause a slight increase in FC [28], but we did not find
any such associations that might explain our results.
Previous studies have shown increased levels of calpro-
tectin in saliva from patients with pSS, suggesting that
calprotectin may originate from the exocrine glands or
may be released in the oral cavity from dry and inflamed
mucosal tissues, possibly both in the GI tract and in the
airways [29]. By analogy to saliva, calprotectin in faeces
could originate from exocrine glands in the bowel. The
tendency toward correlations between ESSDAI and FC
as well as between ESR and FC suggest that FC could be
a marker of disease activity and could possibly be used
in pSS to follow treatment effects in a similar way as in
IBD. Furthermore, the average results from the VAS-IBS
correlated with patient-reported disease activity mea-
sured with the ESSPRI. The aetiology of functional GI
disorders is unknown, but the diseases are characterized
by absence of objective, pathological findings [28]. It re-
mains to be determined whether GI symptoms in pSS
should be defined as functional GI disorders or as a sep-
arate entity of GI disorder associated with pSS.
Some methodological issues have been raised regarding
the measurement of FC, not least because different anti-
bodies are used in the different ELISAs available [21, 30].
The ELISA used in this study has been thoroughly reviewed
and suggested to be superior to some other ELISAs, al-
though conflicting data have been presented [21, 30, 31].
This study has important limitations. Not all patients
had been subject to invasive GI examination, and only
procedures carried out within 1 year of the FC measure-
ment were considered valid for this study, together with
a previous diagnosis of chronic GI disease. It is possible,
therefore, that we underestimated the true prevalence of
organic GI disease in the cohort. In addition, this study
comprised only 56 patients with pSS. Further prospect-
ive studies involving larger patient cohorts that include
routine endoscopy are needed before any firm conclu-
sions can be drawn regarding the pathophysiology be-
hind the elevated FC in pSS.
The prevalence of coeliac disease has been estimated
to be 5 % among patients with pSS [32]. It should be
noted that previous studies have suggested that sero-
logical testing is superior to FC in identifying coeliac dis-
ease in adults [33].
In the field of rheumatology, elevated FC levels have
been reported in systemic sclerosis and ankylosing spon-
dylitis, while knowledge on FC levels in RA is limited
[25, 34, 35]. The role of FC testing in this field is not yet
established, and further studies including FC data on pa-
tients with various rheumatic diseases are warranted.
Conclusions
GI symptoms in pSS are common. Regardless of symp-
toms, FC elevation, especially if >150 μg/g, may indicate
concomitant organic GI disease (e.g., malignancy or
IBD), which warrants further investigation.
Additional file
Additional file 1: Table S1a and S1b. These tables present GI
symptoms in patients with pSS with and without concomitant organic
GI disease. (DOCX 15 kb)
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